Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» rheumatoid arthritis
rheumatoid arthritis
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Tue, 07/2/19 - 10:46 am
Gilead Sciences
AbbVie
FDA
JAK inhibitors
filgotinib
Upadacitinib
rheumatoid arthritis
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
Fri, 06/21/19 - 11:24 am
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Pfizer announces results from XELJANZ XR ORAL Shift study
Pharmaceutical Business Review
Thu, 06/13/19 - 10:05 am
Pfizer
Xeljanz
clinical trials
rheumatoid arthritis
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Wed, 06/12/19 - 06:43 pm
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
Sun, 03/24/19 - 08:08 pm
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
Endpoints
Wed, 03/20/19 - 08:14 pm
Pfizer
Xeljanz
Europe
EMA
rheumatoid arthritis
2 Biotech Stocks With Major Incoming Catalysts
Yahoo/Motley Fool
Thu, 03/7/19 - 09:52 am
Axsome Therapeutics
AXS-05
depression
Galapagos
filgotinib
Gilead Sciences
rheumatoid arthritis
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
CP Wire
Wed, 02/20/19 - 11:52 am
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Wed, 02/20/19 - 11:51 am
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
Pharmaforum
Wed, 02/20/19 - 11:23 am
AbbVie
upadacatinib
FDA
priority review
rheumatoid arthritis
Humira
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Biopharma Dive
Mon, 11/26/18 - 11:13 pm
Gilead Sciences
Galapagos
JAK inhibitors
rheumatoid arthritis
filgotinib
Generic arthritis drug comes up short against inflammation in heart disease
Stat
Sun, 11/11/18 - 09:12 pm
generics
rheumatoid arthritis
methotrexate
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Fierce Biotech
Fri, 11/2/18 - 07:56 pm
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
AbbVie rheumatoid arthritis drug succeeds in late stage trial
Yahoo/Reuters
Tue, 10/23/18 - 10:40 am
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint
Fierce Pharma
Mon, 10/22/18 - 05:15 pm
GSK
rheumatoid arthritis
GSK3196165
clinical trials
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
Yahoo/Motley Fool
Fri, 09/14/18 - 09:36 am
AbbVie
Gilead Sciences
FDA
rheumatoid arthritis
Upadacitinib
filgotinib
Galapagos shares surge on RA drug trial results
Pharmaforum
Thu, 09/13/18 - 10:02 am
Gilead Sciences
Galapagos
filgotinib
rheumatoid arthritis
clinical tgrials
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Fierce Biotech
Thu, 07/5/18 - 07:42 pm
Gilead Sciences
JAK inhibitors
filgotinib
rheumatoid arthritis
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Thu, 06/28/18 - 09:34 am
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
Sun, 06/10/18 - 10:59 am
AbbVie
Huimra
Upadacitinib
rheumatoid arthritis
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »